Whittier Trust Co. Grows Stock Holdings in Cencora, Inc. (NYSE:COR)

Whittier Trust Co. grew its holdings in Cencora, Inc. (NYSE:COR) by 0.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,856 shares of the company’s stock after purchasing an additional 44 shares during the quarter. Whittier Trust Co.’s holdings in Cencora were worth $1,765,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of COR. Raymond James Financial Inc. purchased a new position in Cencora in the 4th quarter worth approximately $322,460,000. Wellington Management Group LLP lifted its stake in Cencora by 7.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company’s stock worth $1,168,927,000 after purchasing an additional 338,452 shares in the last quarter. Amundi lifted its stake in Cencora by 30.8% in the 4th quarter. Amundi now owns 1,338,710 shares of the company’s stock worth $318,385,000 after purchasing an additional 314,846 shares in the last quarter. Nordea Investment Management AB lifted its stake in Cencora by 40.2% in the 4th quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company’s stock worth $243,173,000 after purchasing an additional 308,773 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its stake in Cencora by 21.7% in the 3rd quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company’s stock worth $368,771,000 after purchasing an additional 292,600 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Cencora

In related news, CAO Lazarus Krikorian sold 2,000 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the sale, the chief accounting officer now directly owns 20,154 shares of the company’s stock, valued at $5,241,249.24. The trade was a 9.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of the business’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,970 shares of company stock valued at $2,998,670 over the last ninety days. Insiders own 10.80% of the company’s stock.

Cencora Price Performance

Cencora stock opened at $266.91 on Friday. The stock has a market cap of $51.76 billion, a P/E ratio of 37.97, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The company has a fifty day simple moving average of $250.62 and a 200-day simple moving average of $240.06. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $271.08. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.82%. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Analyst Ratings Changes

A number of analysts have recently issued reports on COR shares. Wells Fargo & Company raised their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a report on Friday, March 14th. Evercore ISI raised their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. JPMorgan Chase & Co. raised their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. StockNews.com upgraded shares of Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Finally, Mizuho started coverage on shares of Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target for the company. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and a consensus target price of $280.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.